|
Published online before print February 25, 2009, doi:10.1212/01.wnl.0000345968.05959.cf)
© 2009 American Academy of Neurology Botulinum toxin for diabetic neuropathic painA randomized double-blind crossover trialFrom the Department of Neurology (R.-Y.Y., J.-J.S., J.-M.Y., C.-J.H.), Taipei Medical University and Hospital; The Neurologic Institute (W.-T.C.), Taipei Veterans General Hospital; College of Nursing (I.-J.T.), Taipei Medical University; Department of International Trade (H.-H.C.), Chungyu Institute of Technology, Keelung; and Department of Neurology (C.-J.H.), Taipei Medical University, Shuang-Ho Hospital, Taiwan. Address correspondence and reprint requests to Dr. Chaur-Jong Hu, Department of Neurology, Taipei Medical University Hospital and Shuang Ho Hospital, 252 Wu-Hsing Street, Taipei 110, Taiwan chaurjongh{at}tmu.edu.tw Background: Diabetic neuropathy is a common complication in diabetes, with patients typically experiencing diverse sensory symptoms including dysesthesias in the feet and usually accompanied by sleep disturbance. There is still no comprehensive understanding of the underlying biologic processes responsible for diabetic neuropathic pain. Thus, the current symptomatic therapy remains unsatisfactory. Recent experimental evidence suggests that botulinum toxin type A (BoNT/A) may not only inhibit the release of acetylcholine at the neuromuscular junctions, but also modulate afferent sensory fiber firing, thereby relieving neuropathic pain. Methods: A double-blind crossover trial of intradermal BoNT/A for diabetic neuropathic pain in 18 patients was conducted to evaluate the effectiveness.
Results: We find significant reduction in visual analog scale (VAS) of pain by 0.83 ± 1.11 at 1 week, 2.22 ± 2.24 at 4 weeks, 2.33 ± 2.56 at 8 weeks, and 2.53 ± 2.48 at 12 weeks after injection in the BoNT/A group, as compared to the respective findings for a placebo group of 0.39 ± 1.18, –0.11 ± 2.04, 0.42 ± 1.62, and 0.53 ± 1.57 at the same timepoints (p < 0.05). Within the BoNT/A group, 44.4% of the participants experienced a reduction of VAS Conclusions: This pilot study found that botulinum toxin type A significantly reduced diabetic neuropathic pain and transiently improved sleep quality. Further large-scaled study is warranted.
Abbreviations: BoNT/A = botulinum toxin type A; CMAP = compound motor action potential; CPSQI = the Chinese version of the Pittsburgh Sleep Quality Index; MCS = Mental Component Summary; NCV = nerve conduction velocity; NE = neurologic examination; PCS = Physical Component Summary; SAP = sensory action potential; SF-36 = Short Form–36 quality-of-life questionnaire; SONO = sonography study of feet for exclusion of peripheral artery occlusion; VAS = visual analog scale.
e-Pub ahead of print on February 25, 2009, at www.neurology.org. Disclosure: The authors report no disclosures. Received July 4, 2008. Accepted in final form December 16, 2008.
Related Article
This article has been cited by other articles:
Correspondence:Read all Correspondence
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 within 3 months after injection, whereas there was no similar response in the placebo group. At the 4-week postinjection stage, improvement in sleep quality was measured using the Chinese version of the Pittsburgh Sleep Quality Index. 
